Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Positive efficacy and safety results reported for IDEC-Y2B8/Rituxan in NHL

Oct. 29, 1998

Japanese patent allowed for Maxamine technology

Oct. 22, 1998

Coulter announces positive investigational phase III results from Bexxar in NHL

Oct. 22, 1998

Endorex adds second site to phase II ImmTher trial

Oct. 16, 1998

Rituximab now available in Germany

Oct. 14, 1998

Antibody-based cancer product from AltaRex heading for phase I testing

Oct. 14, 1998

Coulter initiates expanded access program for Bexxar

Oct. 8, 1998

Patent issued for Neoprobe's RIGS/ACT anticancer technology

Oct. 7, 1998

Genentech's Herceptin given FDA approval

Sep. 28, 1998

Enzon's PEG-Intron A advances to phase III trials for malignant melanoma

Sep. 24, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...